Go or no go? Esperion's double whammy and a look to priority reviews
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
